PacBio has released new software, which has increased read lengths and throughput, and aims to launch a new sample prep protocol and chemistry this year.
Although PacBio's product and services revenues were up 17 percent, total revenues declined 3 percent due to a lack of contractual revenue in the quarter.
PacBio recently launched a new sequencing chemistry for Sequel that increases read lengths, and plans to double the platform's throughput by the end of the year.
